Resectable Pancreatic Cancer Clinical Trial
Official title:
A Prospective, Phase II Study Evaluating the Efficacy of Intraoperative Radiotherapy After Neoadjuvant Chemotherapy in Patients With Resectable Pancreatic Cancer
Verified date | April 2024 |
Source | Gangnam Severance Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.
Status | Active, not recruiting |
Enrollment | 80 |
Est. completion date | April 1, 2026 |
Est. primary completion date | April 1, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years and older |
Eligibility | Inclusion Criteria: - Histologically diagnosed with adenocarcinoma of the pancreas or clinically diagnosed with imaging examinations or tumor markers - 20 years or older - Performance status 0-2 based on Eastern Cooperative Oncology Group (ECOG) - Patients with surgically resectable or borderline resectable and advanced pancreatic cancer that can be resected after neoadjuvant chemotherapy - Patients who voluntarily decided to participate in this clinical study and signed a written informed consent Exclusion Criteria: - History of previous abdominal irradiation. - When the treatment area is not included in the appropriate radiation field according to the judgment of the radiation oncologist or Durgeon - Distant metastasis - Other systemic conditions that, under the judgment of the attending physician, would be difficult to undergo surgery or radiiotherapy |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Gangnam Severance Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yona Cho |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3-year local recurrence rate | A local recurrence is defined as reappearance of cancer in the ipsilateral preserved breast or chest wall.
The 3-year local recurrence rate is calculated using the Kaplan-Meier method. |
3 year after intraoperative radiotherapy | |
Secondary | post-operative complication | Evaluation of safety, including adverse events, was performed by the Principal Investigator and delegated participating investigators in the Department of Surgery and Radiation Oncology outpatient clinic.
Toxicity is evaluated within 3 months (acute) and thereafter (chronic) after surgery, and it is performed through a questionnaire and physical examination at every visit up to 1 year after surgery and recorded. |
3 year after intraoperative radiotherapy | |
Secondary | disease free survival | Disease-free survival is defined as the time from intraoperative radiotherapy to recurrence of tumor, death or last patient contact. | 1 year and 2 year after intraoperative radiotherapy. | |
Secondary | Overall survival | Overall survival was defined as the time from intraoperative radiotherapy to death or last patient contact. | 1 year and 2 year after intraoperative radiotherapy. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05209074 -
Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
|
Phase 1 | |
Not yet recruiting |
NCT05529940 -
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
|
Phase 3 | |
Terminated |
NCT02345460 -
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
|
Phase 2 | |
Recruiting |
NCT02243007 -
Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Recruiting |
NCT05679050 -
Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer
|
Phase 2 | |
Withdrawn |
NCT01694589 -
A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
|
Phase 0 | |
Active, not recruiting |
NCT03138720 -
Pre-operative Treatment for Patients With Untreated Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT01298011 -
Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT06363084 -
A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
|
||
Recruiting |
NCT04810910 -
Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy
|
Phase 1 | |
Completed |
NCT01992705 -
Borderline Pancreas Study: FOLFIRINOX +SBRT
|
Early Phase 1 | |
Recruiting |
NCT05624918 -
A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma
|
Phase 2 | |
Completed |
NCT02047513 -
Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer
|
Phase 2 | |
Completed |
NCT02115022 -
EUS vs. MDCT in Pancreatic Malignancy
|
||
Recruiting |
NCT03492671 -
Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer
|
Phase 2 | |
Terminated |
NCT05546411 -
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
|
Phase 2 | |
Not yet recruiting |
NCT06172036 -
Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab
|
Phase 2 | |
Recruiting |
NCT05788744 -
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer
|
N/A | |
Recruiting |
NCT04737551 -
Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
|
||
Recruiting |
NCT03822936 -
Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma
|
Phase 2 |